ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter
Fiscal Year 2013 Financial Results
WALTHAM, Mass. -- April 18, 2013
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer therapeutics, today announced that the Company will host a
conference call at 8:00 a.m. ET on Friday, April 26, 2013, to discuss
ImmunoGen's financial results for the three-month period ended March 31, 2013
– the third quarter of the Company’s 2013 fiscal year.
To access the live call by phone, dial 913-312-0843. Passcode: 4566767. The
call also may be accessed through the Investor Information section of the
Company's website, www.immunogen.com. Following the live webcast, a replay of
the call will be available at the same location through May 10, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal
antibody to deliver one of ImmunoGen's highly potent cancer-cell killing
agents specifically to tumor cells. Ten TAP compounds are now in the clinic,
of which three are wholly owned by the Company. The most advanced compound
using ImmunoGen's TAP technology, KADCYLA (formerly T-DM1), has been approved
for marketing in the US and is undergoing regulatory review in Europe and
Japan; it is being commercialized in the US by Genentech, a member of the
Roche Group. More information about ImmunoGen can be found at
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Press spacebar to pause and continue. Press esc to stop.